| Drug Type Antibody fusion proteins | 
| Synonyms LP-008, LP008 | 
| Target | 
| Action inhibitors | 
| Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TGFBR2 inhibitors(Transforming growth factor beta receptor 2 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseIND Approval | 
| First Approval Date- | 
| Regulation- | 










| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Solid tumor | IND Approval | China  | 18 Mar 2022 | 






